Table 4.

The network meta-analysis of PFS in BRCA-mutated patients.

Olaparib	0.87(0.56, 1.36)	0.80(0.50, 1.27)	3.47(2.66, 4.54)
1.15(0.74, 1.79)	Niraparib	0.92(0.55, 1.54)	3.98(2.80, 5.67)
1.25(0.79, 1.99)	1.09(0.65, 1.83)	Rucaparib	4.35(2.98, 6.34)
0.29(0.22, 0.38)	0.25(0.18, 0.36)	0.23(0.16, 0.34)	Placebo

The data in bold are statistically significant.